TY - JOUR T1 - Genetically predicted serum vitamin D and COVID-19: a Mendelian randomization study JF - medRxiv DO - 10.1101/2021.01.29.21250759 SP - 2021.01.29.21250759 AU - Bonnie K Patchen AU - Andrew G Clark AU - Dana B Hancock AU - Nathan Gaddis AU - Patricia A Cassano Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250759.abstract N2 - Objectives To investigate causality of the association of serum vitamin D with the risk and severity of COVID-19 infection.Design Two-sample Mendelian randomization study.Setting Summary data from genome-wide analyses in the population-based UK Biobank and SUNLIGHT Consortium, applied to meta-analyzed results of genome-wide analyses in the COVID-19 Host Genetics Initiative.Participants 17,965 COVID-19 cases including 11,085 laboratory or physician confirmed cases, 7,885 hospitalized cases, and 4,336 severe respiratory cases, and 1,370,547 controls, primarily of European ancestry.Exposures Genetically predicted variation in serum vitamin D status, based on genome-wide significant single nucleotide polymorphisms (SNPs) associated with serum vitamin D or risk of vitamin D deficiency/insufficiency.Main outcome measures Susceptibility to and severity of COVID-19 infection, including severe respiratory infection and hospitalization.Results Mendelian randomization analysis, powered to detect moderate effects comparable to those seen in observational studies, provided little to no evidence for an effect of genetically predicted serum vitamin D on susceptibility to or severity of COVID-19 infection. Using SNPs in loci related to vitamin D metabolism as proxies for serum vitamin D concentration, the odds ratio for a standard deviation increase in serum vitamin D was 1.04 (95% confidence interval 0.92 to 1.18) for any COVID-19 infection versus population controls, 1.05 (0.84-1.31) for hospitalized COVID-19 versus population controls, 0.96 (0.64 to 1.43) for severe respiratory COVID-19 versus population controls, 1.15 (0.99 to 1.35) for COVID-19 positive versus COVID-19 negative, and 1.44 (0.75 to 2.78) for hospitalized COVID-19 versus non-hospitalized COVID-19. Results were similar in analyses that used all SNPs with genome-wide significant associations with serum vitamin D (i.e., including SNPs in loci with no known relationship to vitamin D metabolism) and in analyses using SNPs with genome-wide significant associations with risk of vitamin D deficiency or insufficiency.Conclusions These findings suggest that genetically predicted differences in long-term vitamin D nutritional status do not causally affect susceptibility to and severity of COVID-19 infection, and that associations observed in previous studies may have been driven by confounding. These results do not exclude the possibility of low-magnitude causal effects, nor do they preclude potential causal effects of acute responses to therapeutic doses of vitamin D. Future directions include extension of this work to non-European ancestry populations, and high-risk populations, for example persons with comorbid disease.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form and declare: no support from any organization for the submitted work; BKP was supported by the National Institutes of Health during the conduct of the study, AGC, DBH and PAC report receiving grants from the National Institutes of Health during the conduct of the study; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementBKP was supported by the National Institutes of Health under award T32-DK007158. ACG was supported by the National Institutes of Health under award R01-HG006849. NG, DBH and PAC were partially supported by the National Institutes of Health under award R01-HL149352. The study content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. The funders had no role in the study design, data collection, analysis, interpretation, or writing, nor in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The main analysis conducted in this study used publicly available summary data and did not require ethical approval. The use of UK Biobank data for the stratified analysis of SNP-vitamin D associations by COVID-19 risk factors was approved by the Institutional Review Board at RTI International.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for this analysis are publicly available. Code implementing the MR analysis is available upon request from the corresponding author. https://www.covid19hg.org/results/ ER -